PYC Therapeutics
PYC Therapeutics is a clinical-stage biotech company focused on developing RNA therapies to address genetic diseases. Their proprietary RNA delivery platform aims to provide safer and more effective treatments by targeting the underlying causes of these diseases. The company is advancing a pipeline of novel therapies for eye, central nervous system, and kidney diseases.
Short position
PYC Therapeutics (ASX:PYC) has 0.82% of its shares on issue reported as short positions as of 5 Oct 2026, or about 8,063,670 shares. Over the past 30 days that figure has risen 0.79 percentage points, and over 90 days it has risen 0.48 percentage points. Its highest recorded short interest was 1.09% in September 2026. PYC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PYC Therapeutics (PYC) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $39.7MM (source: ASX (Markit))vs $26.2MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −$43.3Mvs −$50.3M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.059T (source: Derived: trailing 12 months at year end)vs −$0.098 (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- +51.6%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- −208.4%
- Net margin
- −109.2%
- FCF margin
- −113.5%
- ROE
- −10.0%
- ROA
- −9.7%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $53.6M
- Net debt / EBITDA
- n/a
- Current ratio
- 33.5×
- Interest cover
- −2,043.2×
- Cash dividends paid / net profit
- n/a
- Market cap
- $2.41B
- P/E
- n/a
- P/B
- 3.5×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $39.7MM (source: ASX (Markit)) | $26.2MM (source: ASX (Markit)) | $22.9MM (source: ASX (Markit)) | $15.9MM (source: ASX (Markit)) |
| Operating income | −$82.7M | −$75.9M | −$60.4M | −$39.2M |
| EBITDA | −$43.1M | −$50.4M | −$37.5M | −$22.8M |
| EBIT | −$43.7M | −$51.0M | −$38.1M | −$23.3M |
| Interest expense | $40.5K | $62.2K | $49.2K | $27.3K |
| Pretax income | −$43.8M | −$51.0M | −$38.1M | −$23.4M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$43.3M | −$50.3M | −$37.7M | −$22.8M |
| Net interest income | $13.6M | $2.6M | $746.8K | $54.6K |
| EPS basic | −$0.059T (source: Derived: trailing 12 months at year end) | −$0.098 | −$0.093 | −$0.068 |
| EPS diluted | −$0.059T (source: Derived: trailing 12 months at year end) | −$0.098 | −$0.093 | −$0.068 |
| Shares | 983.5M | 597.3M | 480.4M | 356.0M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4EAnnual Results28 Aug 2026via asx_announcements
- 2026 Annual Report to ShareholdersAnnual Report28 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results23 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Jan 2026via asx_announcements
- Financial ReportFinancial Report31 Dec 2025via crawler
- Financial ReportFinancial Report31 Dec 2025via crawler
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report27 Oct 2025via asx_announcements
- Appendix 4EAnnual Results28 Aug 2025via asx_announcements
Showing 10 of 30 reports